Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amarin (AMRN) and Amneal Pharmaceuticals Inc (AMRX).
Amarin (AMRN)
Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Amarin today and set a price target of $35. The company’s shares closed yesterday at $16.69.
Chen wrote:
“We think the peak sales potential of Vascepa is underappreciated. Therefore, upward earnings revisions to levels not reflected in FactSet consensus expectations should drive AMRN shares higher. Valuation Summary We continue to use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $35.”
According to TipRanks.com, Chen is a 4-star analyst with an average return of 6.2% and a 35.8% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Amneal Pharmaceuticals Inc, and Aridis Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Amarin with a $34.80 average price target.
See today’s analyst top recommended stocks >>
Amneal Pharmaceuticals Inc (AMRX)
Morgan Stanley analyst David Risinger downgraded Amneal Pharmaceuticals Inc to Hold today and set a price target of $18. The company’s shares closed yesterday at $16.33.
According to TipRanks.com, Risinger is ranked 0 out of 5 stars with an average return of -9.0% and a 39.8% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Assertio Therapeutics Inc, and Elanco Animal Health Inc.
Currently, the analyst consensus on Amneal Pharmaceuticals Inc is a Moderate Buy with an average price target of $21.25.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
